This study investigates pancreatic cancer. It focuses on using the Lewis antigen assay combined with the CA19-9 assay to assess the prognosis of patients.
The study evaluates how the presence of Lewis antigens can predict the severity of pancreatic cancer. It looks at the relationship between these assays and patient outcomes.
- Who can participate: Adults aged 18 to 75 years with pancreatic ductal adenocarcinoma can join. Participants must be able to understand and sign an informed consent form, and have an ECOG status of 0-2.
- Study details: Participants will undergo routine CA19-9 testing and Lewis antigen sample collection.